United States — Centers for Disease Control and Prevention & AstraZeneca

United States — Centers for Disease Control and Prevention: The United States — Centers for Disease Control and Prevention>>> declared the Ebola outbreak a Public Health Emergency of Continental Security, emphasizing the urgency of coordinated action and mobilizing resources for response and preparedness.

AstraZeneca: AstraZeneca was involved in the development of the COVID-19 vaccine platform that is now being considered for a Bundibugyo ebolavirus vaccine, showcasing its role in vaccine innovation.

United States — Centers for Disease Control and Prevention: Launched a response plan with WHO to improve coordination and surveillance across Africa.

AstraZeneca: Technology from its COVID-19 vaccine is used in the Oxford Ebola vaccine, indirectly involved.

United States — Centers for Disease Control and Prevention: CDC's advisory committee may recommend mFLUSIVA, which would influence coverage and uptake; its recommendation is pending.

AstraZeneca: AstraZeneca's flu vaccine portfolio could be affected by the entry of mFLUSIVA.

United States — Centers for Disease Control and Prevention: United States — Centers for Disease Control and Prevention>>> declared the current outbreak a Public Health Emergency of Continental Security, highlighting the regional impact and need for intervention.

AstraZeneca: AstraZeneca is mentioned in the context of the University of Oxford's vaccine technology, which is similar to their COVID-19 vaccine.

United States — Centers for Disease Control and Prevention: US agency providing clinical guidance on Ebola. Its expertise is relevant.

AstraZeneca: Its COVID-19 vaccine technology is used in the Oxford candidate, but AstraZeneca itself is not directly involved in the Ebola response.

United States — Centers for Disease Control and Prevention: The US CDC has also revised its guidance toward a risk-based approach, but a federal court blocked its January 2026 update; an appeal is ongoing.

AstraZeneca: AstraZeneca's vaccine was previously suspended for under 60s in Germany in 2021 due to blood clot concerns; not directly affected by current policy.